Detection of intracellular DNA triggers activation of the stimulator of IFN genes–dependent IFN-stimulatory DNA (ISD) pathway, which is essential for antiviral immune responses. However, chronic activation of this pathway is implicated in autoimmunity. Mutations in TREX1, a 3′ repair exonuclease that degrades cytosolic DNA, cause Aicardi–Goutières syndrome and chilblain lupus. Trex1−/− mice develop lethal, IFN-driven autoimmune disease that is dependent on activation of the ISD pathway, but the DNA sensors that detect the endogenous DNA that accumulates in Trex1−/− mice have not been defined. Multiple DNA sensors have been proposed to activate the ISD pathway, including cyclic GMP–AMP synthase (cGAS). In this study, we show that Trex1−/− mice lacking cGAS are completely protected from lethality, exhibit dramatically reduced tissue inflammation, and fail to develop autoantibodies. These findings implicate cGAS as a key driver of autoimmune disease and suggest that cGAS inhibitors may be useful therapeutics for Aicardi–Goutières syndrome and related autoimmune diseases.
Detection of intracellular nucleic acids and production of type I IFNs are essential for antiviral immunity. The RNA helicases RIG-I and MDA5 sense intracellular RNA and signal via MAVS to promote IFN production, whereas cyclic GMP–AMP synthase (cGAS) detects intracellular DNA ligands and signals via the adaptor stimulator of IFN genes (STING) to trigger the IFN-stimulatory DNA (ISD) response (1). cGAS is a nucleotidyltransferase that directly binds dsDNA in the cytosol and, upon DNA binding, catalyzes the production of cyclic GMP–AMP (cGAMP), which directly binds to and activates STING, triggering production of type I IFNs (2, 3). Studies with cGAS-deficient mice have shown that cGAS is required for the IFN response to transfected DNA ligands, infection with DNA viruses, and retrovirus infection (4–8).
Although critical for antiviral immunity, innate nucleic acid sensing pathways must be tightly regulated to avoid an IFN response against endogenous nucleic acid ligands. The 3′ repair exonuclease Trex1, which degrades cytosolic DNA, is a key regulator of the ISD pathway (9). Loss of function mutations in TREX1 cause Aicardi–Goutières syndrome (AGS), a rare autoimmune disease that presents in neonates with clinical features that mimic congenital viral infection (10). AGS patients exhibit elevated type I IFNs, encephalopathy, psychomotor retardation, and premature death (11, 12). Currently, no ameliorative treatments exist for AGS patients (13). TREX1 mutations also cause familial chilblain lupus and retinal vasculopathy with cerebral leukodystrophy and are associated with systemic lupus erythematosus (14–18).
Trex1−/− mice recapitulate many of the key features of AGS and are a tractable model to study AGS disease mechanisms. Trex1-deficient cells accumulate endogenous DNA substrates, including reverse-transcribed retroelement cDNA, that trigger excessive production of type I IFNs, resulting in lethal autoimmune disease (9). Autoimmune disease in Trex1−/− mice is dependent on activation of the ISD pathway, as Trex1−/− mice that lack STING, IFN regulatory factor 3, the type I IFN receptor, or lymphocytes are completely protected from lethality and tissue destruction (9, 19). However, the DNA sensors that detect these endogenous DNA substrates that accumulate in Trex1−/− mice and trigger IFN production have not been defined. cGAS is a key DNA sensor that activates the ISD response, yet multiple other DNA sensors have been proposed to activate this pathway, including DAI (20), DDX41 (21), and the AIM2-like receptors, IFI16, IFI204, and IFI203 (22–24). One recent study demonstrated that depletion of cGAS within Trex1−/− mouse embryonic fibroblasts reduced the type I IFN gene signature that is present within these cells (25). However, nothing is known about the in vivo role of cGAS in autoimmune pathology. In this study, we demonstrate that cGAS is essential for all aspects of the autoimmune disease in Trex1−/− mice, providing further evidence for its central role as an ISD sensor and revealing a new therapeutic target for AGS and related diseases.
Materials and Methods
We generated cGAS−/− (Mb21d1−/−) mice by in vitro fertilization of C57BL/6J oocytes with frozen sperm carrying a knockout first null allele of cGAS from the International Knockout Mouse Consortium [C57BL/6N-Mb21d1tm1a(EUCOMM)Hmgu, http://www.mousephenotype.org/data/alleles/MGI:2442261/tm1a(EUCOMM)Hmgu]. Mice were genotyped using the following primers: wild-type forward, 5′-GCTGTCTCCACTTGGGCATCT-3′; knockout forward, 5′-AGATGGCGCAACGCAATTAATG-3′; common reverse, 5′-AAGCAGCCACATGAATAGTCTC-3′. cGAS-deficient mice with the knockout first null allele of cGAS were intercrossed with Trex1−/− mice to generate cGAS−/−Trex1−/− mice. Trex1−/−, Tmem173−/−, and Rag2−/− mice have been described (19). All mouse studies were carried out in a specific pathogen-free facility at the University of Washington with approval of the University of Washington Institutional Animal Care and Use Committee.
All tissues were fixed in 10% neutral buffered formalin and paraffin embedded. Tissue sections (5 μm) were stained with H&E, and histological scores were evaluated as described (19).
Detection of autoantibodies
Cell treatments and analysis
Primary mouse bone marrow–derived macrophages and embryonic fibroblasts were cultured, transfected with nucleic acid ligands, and Ifnb mRNA and type I IFN induction were measured as described (26).
Detection of cGAMP by liquid chromatography–tandem mass spectrometry
Mouse hearts were homogenized in extract buffer (50 mM HEPES, 2mM EDTA) at a ratio of 0.1 g heart tissue per 1 ml buffer. Ice-cold methanol was added to 80% final concentration. Extracts were spiked with isotope-labeled cGAMP (cGAMP*) at 10 nM, sonicated, cleared three times by centrifugation at 16,000 × g, lyophilized, and resuspended in water. Detection of cGAMP in heart lysates was performed with liquid chromatography–tandem mass spectrometry as described (27) with the following modifications. cGAMP* (12C1013C10H2415N514N5O13P2, molar mass of 689 g/mol), synthesized with recombinant cGAS and per labeled [13C], 15N-ATP, and natural abundance GTP, was used as an internal standard. Both cGAMP and cGAMP* were eluted at 2.7 min. The following multiple reaction monitoring transitions were detected: cGAMP, +675.1/152.1 (qualifier), +675.1/136.0 (quantifier); cGAMP*, +690.0/146.0 (quantifier). A standard curve was constructed using standard 1 (250 nM cGAMP*, 10 nM cGAMP) and standard 2 (250 nM cGAMP*, 1000 nM cGAMP).
Results and Discussion
cGAS is required for lethal autoimmunity in Trex1-deficient mice
To explore cGAS function in vivo, we generated cGAS-deficient mice from frozen sperm carrying a null allele of cGAS (cGAS−/−, also referred to as Mb21d1−/−, Supplemental Fig. 1). cGAS-deficient mice were physically indistinguishable from their wild-type littermates (data not shown). Moreover, consistent with recent studies (5), the IFN response to transfected DNA in cGAS−/− bone marrow macrophages (Supplemental Fig. 2A, 2B) and embryonic fibroblasts (Supplemental Fig. 2C, 2D) was dramatically impaired and similar to STING-deficient cells, whereas the response to transfected RNA remained intact.
To determine whether cGAS is required for autoimmune disease in Trex1-deficient mice, we intercrossed Trex1−/− and cGAS−/− mice and monitored survival. Trex1 and cGAS are genetically linked, separated by 16 cM on chromosome 9. For this reason, recovery of cGAS−/−Trex1−/− mice from intercrosses of cGAS+/−Trex1+/− mice occurred at a much lower frequency than would be expected with unlinked genes. In contrast to cGAS+/+Trex1−/− mice, which succumbed to lethal disease as expected, cGAS−/−Trex1−/− mice were completely protected from lethality (Fig. 1). Trex1−/− mice heterozygous for cGAS were partially rescued from death, similar to Irf3+/−Trex1−/− mice (9). This contrasts with Trex1−/− mice lacking a single copy of Tmem173 (which encodes STING), which are completely protected from lethal disease (19).
cGAS promotes autoimmune tissue destruction in Trex1−/− mice
Trex1-deficient mice develop multiorgan inflammation, including severe inflammatory myocarditis that is dependent on type I IFNs and STING (9, 19). To determine whether cGAS is required to drive autoimmune tissue destruction, we performed a blinded histological analysis of tissues from cGAS−/−Trex1−/− mice compared with cGAS+/+Trex1−/−, cGAS+/−Trex1−/−, and cGAS−/−Trex1+/+ mice. Consistent with previous studies, we found evidence of inflammation in multiple tissues from cGAS+/+Trex1−/− mice, including the heart, skin, glandular stomach, skeletal muscle, tongue, and kidney, whereas the brain was unaffected (Fig. 2). Heart tissue from Trex1−/− mice was characterized by focally extensive subendocardial and perivascular lymphoplasmacytic myocarditis (Fig. 2A, left panel). Skin tissue exhibited focally extensive proliferative dermatitis with lymphoplasmacytic and lesser neutrophilic cellulitis and myositis (Fig. 2A, middle panel). Finally, the glandular stomach was characterized by diffuse moderate proliferative gastritis with multifocal lymphoid aggregates (Fig. 2A, right panel). In contrast, analysis of heart and skin tissue from cGAS−/−Trex1−/− mice revealed no signs of inflammation (Fig. 2). Mild inflammation was observed in glandular stomach, skeletal muscle, tongue, and kidney tissue from cGAS−/−Trex1−/−mice, which was similar to cGAS−/−Trex1+/+ mice and clearly distinct from that observed in cGAS+/+Trex1−/− mice (Fig. 2B and data not shown). For example, multifocal lymphoid aggregates were not detected in glandular stomach tissue from cGAS−/−Trex1−/− mice, and the mild inflammation observed in these mice was in a distinct region of the stomach (margo plicatus/limiting ridge) compared with cGAS+/+Trex1−/− mice (Fig. 2A and data not shown). Thus, cGAS−/−Trex1−/− mice are protected from tissue destruction, similar to Tmem173−/−Trex1−/− mice (9, 19), indicating that the cGAS/STING ISD pathway is required to drive autoimmune tissue destruction in Trex1-deficient mice.
cGAS drives the autoantibody response in Trex1−/− mice
Trex1-deficient mice develop a T cell–dependent autoantibody response against heart tissue Ags that is dependent on IFN regulatory factor 3 and type I IFN signaling (9, 19). To determine whether cGAS is required for the development of these autoantibodies, we blotted heart tissue extracts with sera from cGAS+/+Trex1−/−, cGAS+/−Trex1−/−, and cGAS−/−Trex1−/− mice. Sera from multiple cGAS+/+Trex1−/− and cGAS+/−Trex1−/− mice exhibited strong autoreactivity against heart extracts (Fig. 3A, left panels). The Ag specificities of these heart autoantibodies were variable among different mice, consistent with our previous analysis of Trex1-deficient mice (9, 19). In contrast, minimal autoreactivity, similar to that observed in Trex1+/− and Trex1+/+ mice, was observed in sera from cGAS−/−Trex1−/− mice (Fig. 3A, right panels). This demonstrates that cGAS is required for the development of autoantibodies against heart tissue Ags in Trex1-deficient mice.
In addition to the heart-specific autoantibody response, Trex1-deficient mice develop several hallmarks of lupus, including ANAs (19). Whether the development of ANAs in Trex1-deficient mice requires the cGAS/STING ISD pathway has not yet been tested. To explore this question, we evaluated sera from cGAS+/+Trex1−/−, cGAS+/−Trex1−/−, and cGAS−/−Trex1−/− mice for the presence of ANAs by staining HEp-2 cell-coated slides. Consistent with previous work, ANAs with variable signal intensity were observed in sera from all cGAS+/+Trex1−/− mice (n = 7 of 7) and most cGAS+/−Trex1−/− mice (n = 6 of 7) (Fig. 3B). In contrast, ANAs were not detected in sera from age-matched cGAS−/−Trex1−/− mice (n = 0 of 3) (Fig. 3B), indicating that cGAS is required for the development of ANAs in Trex1-deficient mice.
cGAS promotes type I IFN production in Trex1−/− mice
Disease in Trex1-deficient mice is driven by type I IFN signaling, as Ifnar−/−Trex1−/− mice are protected from disease (9). To determine whether cGAS promotes type I IFN production in Trex1−/− mice, we measured a panel of IFN-stimulated genes (ISGs) in total peripheral blood cells from cGAS+/+Trex1−/−, cGAS−/−Trex1−/−, and Trex1+/+ mice. We detected a significant increase in expression of two ISGs, Cxcl10 and Mx1, and a trend toward increased expression of Isg15 and Ifit2 in cells from cGAS+/+Trex1−/− mice compared with Trex1+/+ mice, whereas ISG expression was similar in blood cells from cGAS−/−Trex1−/− and Trex1+/+ mice (Fig. 4A).
In a prior study, we identified a localized focus of IFN-responsive cells at the endocardial surface of the heart in neonatal Trex1-deficient mice, suggesting that disease is initiated in this tissue. To explore the possibility that cGAS is activated in Trex1−/− hearts, we used mass spectrometry to measure cGAMP in Trex1−/− heart tissue. We reproducibly detected elevated levels of cGAMP in heart tissue extracts from cGAS+/+Trex1−/− mice, whereas the cGAMP was low or undetectable in extracts from cGAS−/−Trex1−/− and Trex1+/+ mice (Fig. 4B). We hypothesize that cGAS activation in heart tissue drives lethal myocarditis in Trex1−/− mice. Trex1-deficient mice with a conditional allele of cGAS (Supplemental Fig. 1A) will allow for selective depletion of cGAS in future experiments aiming to define the cell types in which cGAS is required to drive disease.
We provide clear genetic evidence that cGAS is absolutely required for disease in Trex1-deficient mice. cGAS−/−Trex1−/− mice are completely protected from lethality, lack autoimmune inflammation, fail to develop autoantibodies, and lack the peripheral blood IFN signature that is present in plain Trex1−/− mice. Moreover, we show that the inflamed hearts of Trex1−/− mice contain elevated levels of cGAMP, thus demonstrating in vivo activation of cGAS during autoimmune inflammation. Although we cannot rule out the possibility that other DNA sensors proposed to activate the STING-dependent IFN response may contribute to autoimmunity in Trex1-deficient mice, our data suggest that, if other sensors participate, they must do so by functioning together with cGAS, and not as independent sensors. Altogether, our studies demonstrate that cGAS is a key driver of autoimmune disease and suggest that cGAS inhibitors may be useful therapeutics for AGS patients with TREX1 mutations.
We are grateful to the University of Washington Histology and Imaging Core and B. Johnson for histology preparation and members of the Stetson laboratory for helpful discussions.
This work was supported by National Institutes of Health Grant AI084914. D.B.S. is a scholar of the Rita Allen Foundation and a Burroughs Wellcome Investigator in the Pathogenesis of Infectious Disease. E.E.G. is supported by a Cancer Research Institute Irvington postdoctoral fellowship.
The online version of this article contains supplemental material.
Abbreviations used in this article:
cyclic GMP–AMP synthase
stimulator of IFN genes.
The authors have no financial conflicts of interest.